BridgeMD
New treatment option for Liver Cirrhosis
Official title Portal Inflow Modulation Prior to Liver Transplantation in Patients With Increased Risk of Intraoperative Blood Loss
ClinicalTrials.gov ID: NCT07111221
What this study is testing
What is Non-selective beta-blockers?
Non-selective beta-blockers is an investigational medicine, being studied as a potential treatment for liver cirrhosis.
Also referred to as NSBBs.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Liver transplantation is a procedure associated with an exceptionally high risk of blood loss. Liver failure, which is the most common indication for transplantation, not only leads to coagulation disorders but also to the development of portal hypertension.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Qualification for elective liver transplantation from a deceased donor
- Age ≥18 years
- BMI between 18.5 kg/m² and 30 kg/m²
- Informed consent to participate in the study
- Clinically significant portal hypertension
You likely can't join if
- Heart failure (EF \<50%)
- Severe right ventricular failure
- Severe pulmonary hypertension
- Systemic infection
- Portal vein thrombosis (Yerdel \>1)
- Severe coagulopathy (INR \>5)
See the full eligibility criteria
- Qualification for elective liver transplantation from a deceased donor
- Age ≥18 years
- BMI between 18.5 kg/m² and 30 kg/m²
- Informed consent to participate in the study
- Clinically significant portal hypertension
- At least 1 of the following risk factors for massive blood loss:
- Re-transplantation
- Previous surgery in the upper abdomen
- History of esophageal variceal bleeding
- History of spontaneous bacterial peritonitis
- Planned thrombectomy during liver transplantation
- Heart failure (EF \<50%)
- Severe right ventricular failure
- Severe pulmonary hypertension
- Systemic infection
- Portal vein thrombosis (Yerdel \>1)
- Severe coagulopathy (INR \>5)
- Thrombocytopenia \<20,000/ml
- Severe or uncontrolled encephalopathy (ammonia concentration \>100 μmol/l)
- Contraindication to TIPS
- Contraindication to therapy with non-selective beta-blockers
- Pregnancy
- Lack of informed consent to participate in the study
The study team makes the final eligibility decision.
Where it's taking place
- Warsaw, Poland
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Warsaw, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.